Addressing the need for animal free testing of human acute toxicity

XCellR8有限公司的目标是为人类急性口服毒性预测提供第一个完全不含动物的体外测试，将强大的科学基础与非动物方法的伦理优势相结合。针对化妆品行业对科学先进的非动物急性毒性测试的迫切需求，XCellR8开发了一种原理测试证明，以表明这是可以实现的。该行业的公司发现自己陷入了两项相互矛盾的监管之间。XCellR8的S测试表明，有一种方法可以解决这一差距，允许化妆品公司测试新成分，不仅消除了在动物身上进行测试的需要，而且通过使用人类衍生成分提供了比传统啮齿动物模型更准确的人体毒性测试。欧共体资助的一项可行性研究证实，为了释放测试的全部市场潜力，应该扩大预测能力和行业适用性，显著增强商业机会。一系列行业的配料供应商--特别是工业化学品、杀菌剂和农用化学品以及医疗器械--表示对这项测试感兴趣，理由是他们自己的部门也存在类似的相互矛盾的法规。该项目将使XCellR8能够开发一种新的、改进的测试，具有增强其预测能力的功能，并确保其适用于更广泛的行业，从而巩固商业主张。这将有助于建立一家总部位于英国的中小企业XCellR8，成为提供用于人类安全测试的非动物技术的世界领先公司。

XCellR8 Limited aims to offer the first completely animal-free, _in vitro_ test for human acute oral toxicity prediction, combining a strong scientific rationale with the ethical advantages of a non-animal approach.In response to the critical need in the cosmetics sector for scientifically advanced, non-animal tests for acute toxicity, XCellR8 developed a Proof of Principle test to show that this could be achieved. Companies in the sector find themselves stuck between two contradictory regulations. XCellR8's test indicates that there is a way to resolve this gap and allow cosmetic companies to test new ingredients, not only to remove the need to test on animals but also to provide a more accurate test for human toxicity than traditional rodent models by utilising human-derived components.An EC-funded feasibility study confirmed that in order to unlock the full market potential of the test, the predictive capacity and sector applicability should be expanded, significantly enhancing the commercial opportunity. Ingredient suppliers in a range of industries -- notably industrial chemicals, biocides and agrochemicals, and medical devices - expressed an interest in the test, citing similar contradictory regulations in their own sectors.This Project will enable XCellR8 to develop a new, improved test with features that enhance its predictive capacity, and to ensure its applicability to a wider range of sectors, solidifying the commercial proposition. This will aid in establishing a UK-based SME, XCellR8, as a world leading company for the provision of non-animal technologies for the testing of human safety.